Evidence map›Paper›PMID 27417188›Full record

ArticleJournal of immunotoxicology2016

Effect of administration timing of postchemotherapy granulocyte colony-stimulating factor on host-immune cell recovery and CD8

Mohamed Labib Salem, Mohamed Nassef, Soha G R Abdel Salam, Abdelaziz Zidan, Mohamed H Mahmoud, Gamal Badr, Mark Rubinstein, David Cole

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of immunotoxicology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. G-CSF induces CD15Clinical & translational immunology · 2022
    Article
  2. Immunomodulatory Effects ofJournal of immunology research · 2022
    Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Mohamed Labib Salema Immunology and Biotechnology Division, Zoology Department , Tanta University , Tanta , Egypt.
Mohamed Nassefa Immunology and Biotechnology Division, Zoology Department , Tanta University , Tanta , Egypt.
Soha G R Abdel Salama Immunology and Biotechnology Division, Zoology Department , Tanta University , Tanta , Egypt.
Abdelaziz Zidanb Center of Excellence in Cancer Research, Tanta University , Tanta , Egypt.
Mohamed H Mahmoudc Deanship of Scientific Research, King Saud University , Riyadh , Saudi Arabia.
Gamal Badre Laboratory of Immunology and Molecular Biology, Zoology Department, Faculty of Science , Assiut University , Assiut , Egypt.
Mark Rubinsteinf Surgery Department and Hollings Cancer Center , Medical University of South Carolina , Charleston , SC , USA.
David Colef Surgery Department and Hollings Cancer Center , Medical University of South Carolina , Charleston , SC , USA.
Tanta University · EGMedical University of South Carolina · USAssiut University · EGNational Research Centre · EG

Funding

Maximizing Memory T Cell Responses by Matured Post Chemotherapy Dendritic CellsR01CA133503 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI RUBINSTEIN, MARK P · 2010 to 2012
$900k
NCI NIH HHS R01 CA133503
6 · The paper itself

Abstract

Granulocyte colony-stimulating factor (G-CSF), a hematopoietic growth factor, is a standard supportive therapy given during cancer treatment. It induces acceleration in neutrophil recovery through stimulation of mobilization of hematopoietic progenitors. Given that the latter is also induced by chemotherapy itself, the timing of administration of G-CSF postchemotherapy might impact the resultant overall effects. The present study aimed to determine the optimal timing of G-CSF postchemotherapy to exert its optimal effects on the immune cell recovery and its impact on antigen-specific CD8

Indexed as

Adoptive TransferAnimalsCD8-Positive T-LymphocytesCells, CulturedClinical ProtocolsCyclophosphamideDrug-Related Side Effects and Adverse ReactionsDrug TherapyGranulocyte Colony-Stimulating FactorHematopoietic Stem Cell MobilizationHematopoietic Stem CellsHumansMiceMice, Inbred C57BLMice, TransgenicNeoplasmsCyclophosphamideGranulocyte Colony-Stimulating FactorAntigen-specific immunitycyclophosphamideG-CSFpostchemotherapy

Identifiers

PMID27417188
PMCPMC5669798
OpenAlexW2466239071

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.